>>Description of the research protocol "EORTC 1333"

A randomized multicenter phase III trial comparing enzalutamide vs a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.
Phase III study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Cancer
Brugmann identifier : EORTC 1333
EudraCT identifier : 2014-001787-36


Involved department : Radioisotopes
Principal investigator : Hambye
Sponsor : EORTC
Contact : Clinical Research Unit

>This protocol was approved by the UCL St Luc ethics committee.